Glycominds Ltd. Achieves CE MARK For Novel Crohn's Disease Blood Test; US Patent Office Grants GlycoChip Letters Of Allowance
10/19/2005 5:09:48 PM
LOD, Israel--(BUSINESS WIRE)--May 25, 2005--Glycominds announced today that it has achieved the CE MARK of the EU for the marketing of the company's IBDX(TM) products. The IBDX kit is a series of blood tests for Crohn's Disease, enabling differential diagnosis between Crohn's Disease, Ulcerative Colitis and Irritable Bowel Syndrome.
"For the first time there is now a highly-reliable way for doctors to test patients presenting with the very similar symptoms that occur in chronic gastrointestinal conditions," said Avinoam Dukler, Glycominds CEO. "We expect the IBDX(TM) to revolutionize the way in which these conditions are diagnosed. This product line is a significant advance over existing tests, offering a simple non-invasive blood test with improved sensitivity and specificity. The IBDX(TM) kits have nearly 80 percent sensitivity compared to the 50 percent level common in existing tests. In addition, using two different IBDX(TM) markers together increases specificity to 99 percent."
comments powered by